| Date | Title | Description |
| 17.01.2026 | Proxima Secures $80M Seed Round to Redefine Drug Discovery | Proxima, an AI-native biotech firm, secured an $80 million seed funding round. DCVC led the investment. NVentures and other major investors participated. Formerly VantAI, the company now targets proximity therapeutics. It aims to revolution... |
| 14.01.2026 | Proxima: $80 Million Raised To Power The Next Generation Of Proximity-Based Medicines | Proxima, the AI-native biotech company developing drug discovery tools and therapeutics for proximity-based medicines, has raised an oversubscribed $80 million seed round and rebranded from VantAI as it sharpens its focus on proximity thera... |
| 13.01.2026 | Proxima Raises $80M in Seed Funding | Proxima (formerly VantAI), a NYC-based AI-native biotech company developing AI-driven drug discovery for proximity therapeutics, raised $80M in Seed funding.
The round was led by DCVC, with participation from NVentures (NVIDIA’s venture cap... |
| 16.12.2025 | PsiThera Raises $47.5M in Series A Funding | PsiThera, a Watertown, MA-based biotech company which specializes in protein states and computational intelligence, raised $47.5M in Series A funding.
The round was led by Samsara Biocapital and Lightstone Ventures with participation from R... |
| 22.10.2025 | Finith Jernigan, Ph.D.: How to Translate Complex Problems Into Solvable Technology Solutions | Share
Share
Share
Share
Email
When businesses face a challenge, the instinct is often to move quickly toward a solution. Yet without first taking the time to define the problem clearly, even the best efforts can miss the mark. For Finith Je... |
| 19.02.2025 | Zest Health: Virtual Care Company Raises $13 Million (Seed) | Zest Health, which is the first value-based virtual care company focused on treating patients with inflammatory skin diseases, announced $13 million in seed funding. And Zest Health’s platform offers personalized dermatology care that minim... |
| 09.02.2025 | Zest Health: $13 Million (Seed) Raised For Curbing Unnecessary Pharmaceutical Spend | Zest Health, which is the first value-based virtual care company focused on treating patients with inflammatory skin diseases, announced $13 million in seed funding. And Zest Health’s platform provides personalized dermatology care that min... |
| 05.02.2025 | Zest Health's $13M Funding: A New Dawn for Skin Disease Care | In the world of healthcare, innovation is the lifeblood. Zest Health, a New York City-based virtual care company, has just secured $13 million in seed funding. This investment, led by Roivant Health, aims to reshape the landscape of care fo... |
| 03.02.2025 | Zest Health Raises $13M to Transform Inflammatory Skin Disease Care with Virtual, Value-Based Approach | What You Should Know:
– Zest Health, a leading innovator in virtual dermatology care, today announced a $13 million seed funding round led by Roivant Health.
– The company’s AI-powered platform provides personalized care for patients with i... |
| 21.01.2025 | Commentary: Whatever Elon Musk says, DOGE is not the answer to improving productivity | SUTTON, Australia: US President Donald Trump has asked Elon Musk and Vivek Ramaswamy to establish a Department of Government Efficiency – to be known by the acronym DOGE – to “dismantle government bureaucracy, slash excess regulations, cut ... |
| 18.01.2025 | How Donald Trump plans to cement control of government by dismantling the 'deep state' | US President-elect Donald Trump
President-elect Donald Trump is poised to seize greater control of the federal government than any modern president before him when he takes office on Monday, charging ahead with plans to dismantle what he an... |
| 15.11.2024 | The Musk-Trump Efficiency Panel: A New Era of Government Streamlining? | In the world of politics, few names spark as much intrigue as Elon Musk. The billionaire entrepreneur, known for his ventures in electric vehicles and space exploration, is now stepping into the political arena. President-elect Donald Trump... |
| 15.11.2024 | National Politics | 5 takeaways from Trump’s big moves: Meeting with Biden, picking Gaetz for AG | “He is really squeezing the new Senate majority, immediately testing whether they will just go along with whatever he wants,” said Kyle Kondik, a political analyst at the Center for Politics at the University of Virginia.Elon Musk: From cam... |
| 14.11.2024 | Tech billionaire, immigration hardliner, China hawk: Who's who in Trump's top team | Listen to this article
Tech billionaire, immigration hardliner, China hawk: Who's who in Trump's top team
1 min
New: You can now listen to articles.
This audio is generated by an AI tool.
US President-elect Donald Trump has been building hi... |
| 14.11.2024 | How Elon Musk's US government efficiency panel might work | WASHINGTON: President-elect Donald Trump has tasked billionaire Tesla CEO Elon Musk with setting up a panel to streamline the US government. Although Trump has said little about how this group would operate, Musk previously set an ambitious... |
| 13.11.2024 | Trump appoints billionaire Elon Musk, Ramaswamy to lead Government efficiency with “DOGE” Initiative | President Donald J. Trump has announced the appointment of entrepreneur Elon Musk and conservative businessman Vivek Ramaswamy to spearhead the newly established Department of Government Efficiency (DOGE), a key component in the administrat... |
| 24.09.2024 | Biopharmaceuticals on the Rise: A Surge of Innovation and Investment | The biopharmaceutical sector is buzzing. Recent developments reveal a landscape rich with opportunity and innovation. Companies are securing funding, expanding their reach, and launching groundbreaking therapies. This surge is not just a ri... |
| 24.09.2024 | Financial boost for five publicly traded companies |
Altamira Therapeutics, a biopharmaceutical company specializing in RNA-based therapeutics for extrahepatic targets, announced the closing of a public offering raising up to $12.0 million. The offering included Series A-1 and Series A-2 com... |
| 24.08.2024 | The Future of Cryptocurrency: Key Insights from H.C. Wainwright's 26th Annual Global Investment Conference | The cryptocurrency landscape is a shifting terrain. Each year, industry leaders gather to navigate its complexities. The 26th Annual Global Investment Conference, hosted by H.C. Wainwright & Co., is set to take place from September 9-11... |
| 22.08.2024 | H.C. Wainwright Announces 26th Annual Global Investment Conference, September 9-11, 2024. Event Features Leading Industry Keynote Addresses by Vivek Ramaswamy, Michael Saylor; Bitcoin Panel Moderated ... | NEW YORK–(BUSINESS WIRE)–August 22, 2024–
H.C. Wainwright & Co., LLC, a full-service investment bank dedicated to providing corporate finance, strategic advisory, and equity research coverage to public and private companies across multi... |
| 30.04.2024 | HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update | Delivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs.
Phase 3 VELOS-4 study of tanfaner... |
| 04.04.2023 | Highschool Startup Begins User Testing of an Instant and Mobile Test for Early Detection of Neurodegeneration. | Vytal.ai begins user testing for NeurEye, a 30-second test for ocular biometrics indicative of neurodegenerative disease viable on any smartphone. MCLEAN, VA, UNITED STATES, April 4, 2023/EINPresswire.com/ -- After a rapid but thorough deve... |
| 28.02.2023 | Vivek Ramaswamy, a biotech millionaire running against Trump, is a former Harvard rapper and son of Indian immigrant campaigning on 'anti-woke' credentials | Vivek Ramaswamy at CPAC in Dallas, Texas, on August 5, 2022. Brian Snyder/Reuters
Vivek Ramaswamy announced his candidacy for the 2024 GOP presidential nomination on February 21.
The biotech entrepreneur, who is the son of Indian immigrants... |
| 10.06.2022 | “You are able to think big only if you think independently.” | |
| 21.09.2021 | Roivant Sciences Reports First Fiscal Quarter 2021 Financial Results and Provides Business Update | BASEL, Switzerland and LONDON and NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Roivant Sciences Ltd. ("Roivant" or the "Company"), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare... |
| 09.06.2021 | MONTES ARCHIMEDES ACQUISITION CORP.
Montes Archimedes Acquisition : Roivant Provides Corporate Updates | NEW YORK and BASEL, Switzerland, June 9, 2021 /PRNewswire/ -- Roivant Sciences today announced that Datavant, the leader in helping healthcare organizations securely connect their data, and Ciox Health, the leader in clinical data exchange,... |
| 06.05.2021 | SUMITOMO DAINIPPON PHARMA CO., LTD.
Sumitomo Dainippon Pharma : Announces Investment in Special Purpose Acquisition Company Combining with Roivant Sciences | May 6, 2021
Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma Announces Investment in Special Purpose
Acquisition Company Combining with Roivant Sciences
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representa... |
| 04.05.2021 | Swiss biotech company Roivant Sciences to go public via $7.3B SPAC deal | Roivant Sciences, a biopharmaceutical & healthcare technology company, has announced that it is going public via SPAC. The biopharmaceutical and healthcare technology company, and Montes Archimedes Acquisition Corp. (Nasdaq: MAAC), a sp... |
| 03.05.2021 | Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology | NEW YORK, MENLO PARK, Calif., LONDON, and BASEL, Switzerland, May 3, 2021 /PRNewswire/ -- Roivant Sciences, a biopharmaceutical and healthcare technology company, and Montes Archimedes Acquisition Corp. (Nasdaq: MAAC), a special purpose acq... |
| 03.05.2021 | Roivant Sciences to go public via $7.3 billion deal | |
| 03.05.2021 | Roivant Sciences to go public via $7.3 billion deal | Montes Archimedes Acquisition Corp. (MAAC) is a so-called SPAC, a special purpose acquisition company without operations and listed at a stock exchange set up by investors with the sole purpose of acquiring another company. Montes and Roiva... |
| 03.05.2021 | Roivant Sciences to go public through $7.3 billion SPAC deal | Roivant Sciences, the biotech company once pitched as a Berkshire Hathaway for the pharmaceutical industry, is going public, merging with a blank-check company at a $7.3 billion valuation.
In a deal disclosed Monday, Roivant will combine wi... |
| 03.05.2021 | Today in European Tech: Roivant to go public in $7.3 billion deal, Intel to invest $600 million in R&D in Israel, a new Irish unicorn, and more | Hello!
Here's what happened today in European Tech. Deals
- Roivant Sciences has agreed to go public through a merger with a blank-check firm backed by former KKR dealmaker Jim Momtazee, in a deal that values the Swiss biotech company at $7... |
| 26.02.2021 | Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics | NEW YORK & BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Feb 26, 2021--
Roivant Sciences today announced it has entered into a definitive agreement to acquire Silicon Therapeutics for $450 million in Roivant equity, with additional ... |
| 26.02.2021 | Roivant extends AI drug discovery reach with $450M Silicon Therapeutics buyout | New York and Basel, Switzerland-based Roivant is acquiring Silicon Therapeutics, a computational drug discovery startup that has advanced from company launch to clinical testing in four years. Under the terms of the agreement, Roivant will ... |
| 26.02.2021 | Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics | NEW YORK and BOSTON and BASEL, Switzerland, Feb. 26, 2021 /PRNewswire/ -- Roivant Sciences today announced it has entered into a definitive agreement to acquire Silicon Therapeutics for $450 million in Roivant equity, with additional potent... |
| 26.02.2021 | Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics | – Leading computational physics-based platform for design and optimization of small molecules bolsters Roivant’s drug discovery capabilities
– Silicon Therapeutics drug discovery executives Dr. Woody Sherman, Dr. Huafeng Xu, and Dr. Chris W... |
| 09.12.2020 | South Korean conglomerate injects $200 million in Roivant | Roivant Sciences develops medicines by leveraging the Roivant platform to launch "Vants" – nimble and focused biopharmaceutical and health technology start-ups. |
| 09.12.2020 | South Korean conglomerate injects $200 million in Roivant | |
| 07.12.2020 | Roivant gets $200M for major push into protein degradation | Roivant Sciences has secured $200 million to advance its protein degradation ambitions. Armed with the money, Roivant CEO Vivek Ramaswamy plans to use the VantAI platform to spawn multiple new biotech startups.
The potential for protein deg... |
| 07.12.2020 | Roivant gets $200M for major push into protein degradation
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Roivant Sciences has secured $200 million to advance its protein degradation ambitions. Armed with the money, Roivant CEO Vivek Ramaswamy plans to use the VantAI platform to spawn multiple new biotech startups.
Sponsored by Agilent Technolo... |
| 15.10.2020 | It’s Raining Biotech SPACs! | SPACs are all the rage today. With the IPO market booming and public investors seeking better returns, blank check companies called “Special Purpose Acquisition Companies” (SPACs) have been fueling up their tanks and chasing down their merg... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 03.01.2020 | Roivant closes USD $3 billion deal with Sumitomo Dainippon Pharma | |
| 03.01.2020 | Roivant closes USD $3 billion deal with Sumitomo Dainippon Pharma | Sumitovant will operate as a wholly owned subsidiary of Sumitomo Dainippon Pharma and will be the parent company of the five biopharma companies for which Roivant transferred its ownership interest: Myovant Sciences Ltd., Urovant Sciences L... |
| 06.09.2019 | Sumitomo pays $3B to Vivek Ramaswamy’s Roivant under new alliance | The alliance will be wholly owned by Sumitomo, which is also taking over Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and an additional company that remains to be specified. Sumitomo will have the option of a... |
| 26.08.2019 | Venture-backed Modis Therapeutics Acquired By Publicly-held Zogenix for $250M | 7 Shares Email Facebook Twitter LinkedIn
Modis Therapeutics, a venture-backed biopharma company, is being acquired by Zogenix Inc. for $250 million, the companies announced today and as reported by Street Insider.
Subscribe to the Crunchbas... |
| 04.04.2019 | Vivek Ramaswamy launches yet another Vant, this time in Asia with a TCR-focused Medigene partnership | Vivek Ramaswamy’s company-churning shop Roivant is operating at full steam. After unveiling Chinese biopharma upstart Sinovant last year, the two entities on Thursday debuted a fresh cell therapy company — Cytovant ... |
| 13.11.2018 | Roivant raises $200M, at $7B valuation, to add to startup roster | Roivant Sciences has raised $200 million to roll out another round of startups. The financing, which comes 15 months after Roivant raised $1.1 billion, is tied to a $7 billion valuation for the fast-growing biotech umbrella organization.
No... |
| 13.11.2018 | Biotech holding company Roivant Sciences raised $200M in funding at a whopping $7B valuation | Roivant Sciences has had a bumpy couple of years, but that isn’t stopping investors from pouring more money into the four-year-old company, which aims to one day be a giant parent company for dozens of independent biopharmaceutical spinoffs... |
| 13.11.2018 | Roivant raises $200M, at $7B valuation, to add to startup roster | Roivant Sciences has raised $200 million to roll out another round of startups. The financing, which comes 15 months after Roivant raised $1.1 billion, is tied to a $7 billion valuation for the fast-growing biotech umbrella organization.
Sp... |
| 13.11.2018 | Investors Bet $200M On Roivant, A Biopharma Company Now Valued At $7B | 12 Shares Email Facebook Twitter LinkedIn
Swiss biopharmaceutical company Roivant Sciences has raised $200 million, bringing its valuation to $7 billion, according to the company.
Follow Crunchbase News on Twitter
The financing – slated to ... |
| 13.11.2018 | Roivant Sciences Announces $200M Round | Roivant Sciences, a Basel, Switzerland-based developer of rapidly developing innovative medicines through a novel form of industrial organization in R&D, raised $200m in equity financing.
Backers included new investors NovaQuest Capital... |
| 13.11.2018 | Roivant raises $200M in equity financing, valuing company at $7B | Most of the latest round of financing came from new investors NovaQuest Capital Management and RTW Investments, among others. Roivant made headlines in August 2017 when the SoftBank Vision Fund led a $1.1 billion equity investment in the co... |
| 27.03.2018 | Roivant bags China rights to Nabriva's antibiotic; Singapore’s Aslan Pharma lines up an $86M IPO to fund pivotal cancer drug studies | → Roivant Sciences is doubling down on infectious diseases and the China market with a licensing agreement with Nabriva Therapeutics $NBRV, which is expecting data from a second Phase III for its lead antibiotic lefamu... |
| 19.01.2018 | Roivant Sciences to join BaseLaunch Accelerator as Healthcare Partner | |
| 06.10.2017 | Roivant looks to quickly turn the page, starting with a Phase 3 win | A new hormonal therapy designed to treat uterine fibroids called relugolix has finished a Phase 3 study in Japan, and the results are positive.
That’s welcome news for a SoftBank-backed company based in Basel, Switzerland called Roivant Sci... |
| 03.10.2017 | What SoftBank really wants | Some in Silicon Valley aren’t quite sure what to make of SoftBank and its massive, roughly $100 billion Vision Fund. At times, they say privately, it looks like a drunken gunslinger, firing off massive checks in quick succession.
But source... |
| 26.09.2017 | Roivant receives bad news — and so does SoftBank | Last month, SoftBank, through its massive Vision Fund, led the single biggest private financing round for a healthcare company ever — funneling $1.1 billion into the drug holding outfit Roivant Sciences.
Today, the Japanese conglomerate mig... |
| 10.08.2017 | SoftBank's Vision Fund Courts Startups That Mix Data and Pharma
SoftBank's Vision Fund Courts Startups That Mix Data and Pharma | (Bloomberg) -- SoftBank Group Corp.’s Vision Fund is targeting a range of investments in startups that use data to help speed up drug discovery, as the near-$100 billion fund continues its deal spree.
Anglo-Swiss pharmaceutical group Roivan... |
| 10.08.2017 | Roivant Sciences Raises $1.1 Billion | |
| 09.08.2017 | Roivant, which creates companies around abandoned drugs, just raised $1.1 billion from SoftBank | Roivant Sciences, a three-year-old, Basel, Switzerland-based company aiming to one day be a giant holding company for dozens of independent biopharmaceutical companies, has raised $1.1 billion in equity led by the SoftBank Vision Fund — mak... |
| 09.08.2017 | Roivant Sciences Raises $1.1 Billion in Equity Funding | Roivant Sciences, a global healthcare company, raised $1.1 billion in equity funding.
The round was led by the SoftBank Vision Fund, with participation from existing shareholders including the Dexxon investor group.
The company intends to u... |
| 09.08.2017 | Term Sheet — Wednesday, Aug. 9 | ET CETERA
Good morning! I’m attending to some magazine duties today, so here’s some news from my Fortune colleagues:
Paid Content What you need to know about growing cyberattacks From ExtraHop
The event itself was elaborate. After arriving ... |
| 17.04.2017 | Enzyvant secures new Regenerative Medicine Advanced Therapy (RMAT) designation | North Carolina-based Humacyte claimed the first RMAT designation on March 20, 2017, for its investigational human acellular vessel (HAV). On Monday, the less than one-year-old rare disease company Enzyvant claimed the second and a BTD to bo... |
| 10.04.2017 | Axovant hires ex-Medivation CEO as it nears Phase 3 Alzheimer’s readout | That pipeline and commercialization experience could go a long way at Axovant.
Indeed, Wall Street seemed pleased with the announcement. Axovant shares surged 27 percent on Monday morning following the news.
Ramaswamy, a 31-year-old former ... |
| 06.01.2017 | The billion-dollar pharma startup that Silicon Valley has totally missed | When it comes to millennials and healthcare companies, recent history gives plenty of reason for pause. Elizabeth Holmes, the founder and CEO of Theranos, has watched her star fall precipitously over the last year, amid a continuing drumbea... |
| 29.12.2016 | Ambitious young biotech group establishes global headquarters in Basel | |
| 21.12.2016 | Is biopharma’s Midas man Vivek Ramaswamy building a new IPO vehicle with Dermavant deal? | Vivek Ramaswamy
One of Vivek Ramaswamy’s fledgling, pre-IPO “vant” companies has swung another in-licensing deal to beef up its pipeline.
Dermavant Sciences, a subsidiary of Roivant, turned to a struggling Portola $PTLA to ... |
| 27.10.2016 | Myovant Sciences rallies $218 million biotech IPO | At the heart of Myovant’s impressive stock price is an agreement with Takeda Pharmaceuticals, which traded global rights to its small molecule relugolix for minority shares in the company and future royalties. Takeda will retain commercial ... |
| - | Enzyvant secures new Regenerative Medicine Advanced Therapy (RMAT) designation | There are countless nuggets of healthcare gold buried within the almost 1000-page 21st Century Cures Act, signed into law with bipartisan support at the end of 2016.
Among the riches is the Regenerative Medicine Advanced Therapy (RMAT) prog... |
| - | Axovant hires ex-Medivation CEO as it nears Phase 3 Alzheimer’s readout | Five months out from a potentially pivotal data readout on its lead candidate for Alzheimer’s disease, Axovant founder Vivek Ramaswamy has taken a step back, handing the reins to highly-experienced biopharma CEO David Hung.
Hung founded Med... |
| - | Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion | - |
| - | Myovant Sciences rallies $218 million biotech IPO | As the nation slept, women’s health company Myovant Sciences quietly completed the largest biotech initial public offering (IPO) of 2016, amassing $218 million on the New York Stock Exchange. Shares will trade under the ticker symbol (NYSE:... |
| - | Today in European Tech: Roivant to go public in $7.3 billion deal, Intel to invest $600 million in R&D in Israel, a new Irish unicorn, and more | Hello!
Here's what happened today in European Tech. Deals
- Roivant Sciences has agreed to go public through a merger with a blank-check firm backed by former KKR dealmaker Jim Momtazee, in a deal that values the Swiss biotech company at $7... |
| - | Sumitomo pays $3B to Vivek Ramaswamy’s Roivant under new alliance | A Japanese drugmaker plans to acquire several companies from Vivek Ramaswamy’s Vant family of firms under a new alliance between the two.
Basel, Switzerland-based Roivant Sciences and Osaka, Japan-based Sumitomo Dainippon Pharma said Thursd... |
| - | Roivant extends AI drug discovery reach with $450M Silicon Therapeutics buyout | Roivant Sciences has technology that uses computer modeling to design drugs that harness the body’s natural way of disposing of old or damaged proteins. On Friday, the company unveiled a $450 million acquisition that could expand that platf... |
| - | Roivant raises $200M in equity financing, valuing company at $7B | A company developing drugs across a wide variety of therapeutic areas – including several that are in Phase III development – with backing from Japan’s SoftBank has raised $200 million in equity investment.
Roivant Sciences – based in Basel... |
